Amarin (STU:EH3) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:EH3 Amarin Corp PLC STU:EH3
62 GF Score
Price €12.20
GF Value €10.16
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Amarin FFO?

FFO (Funds from operations) only applies to REITs.

STU:EH3
62GF Score
Amarin Corp PLC STU:EH3
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Amarin (STU:EH3) Overvalued in 2026?

Based on GuruFocus' analysis, Amarin stock appears to be overvalued. The current stock price of €12.20 is trading 20.1% above its estimated GF Value™ of €10.16. GuruFocus considers Amarin to be Modestly Overvalued.

Key valuation signals for STU:EH3:

  • FFO:
  • GF Value™: €10.16 vs. price of €12.20 (20.1% above fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the STU:EH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Amarin Business Description

Other Exchanges AMRN:USAEH3:Germany
Address 36 Dame Street, 8th Floor, One Central Plaza, Dublin, IRL, D02 K7K5
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
62GF Score

Get the complete analysis for STU:EH3

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.20
Price
€10.16
GF Value